Abstract: A substrate transfer device includes a casing and a substrate conveying robot. A size of the casing in a second direction Y is more than a size of the casing in a first direction X. The casing includes walls forming a conveying chamber and at least one opening or provided at at least one side of the conveying chamber in the first direction X. The substrate conveying robot includes a base, a robot arm, a robot hand, and a controller. When a space in the conveying chamber except for a predetermined exclusive region is defined as an effective conveying chamber, an entire link length DL of a link is less than a conveying chamber size Dx, and an entire hand length Dh of the robot hand is not less than an effective conveying chamber size Dx?.

Abstract: The invention relates to processes for dry powder blending. Specifically the invention relates to dry powder blending of pharmaceutical and non-pharmaceutical solid particulate matter and powders. More specifically the invention relates to dry powder blending of microparticles, and to dry powder blends for use as pharmaceuticals. In particular, the present invention relates to a process of preparing a dry microparticulate powder blend comprising one or more micronized active pharmaceutical ingredient(s) (API) and optionally, one or more micronized or non-micronized pharmaceutically acceptable carrier(s) and/or excipient(s), wherein the process comprises the steps of ‘pulsating blending’ of the micronized active pharmaceutical ingredient(s) and the pharmaceutically acceptable carrier(s) and/or excipient(s).

Abstract: A method is provided. The method includes: displaying media information which is shared by a Social Networking Service (SNS) platform and released by a second client; displaying an entrance for giving free resources provided by the SNS platform; and in response to an operation for giving free resources triggered through the entrance, sending an instruction for giving free resources for the media information to the SNS platform which transfers a given-free resource from an account of the first client to an account of the second client according to the instruction.

Abstract: A terpolymerized corrosion and scale inhibitor used in circulating cooling water of central air conditioning, containing tourmaline, polyaspartic acid, polyepoxysuccinic acid, polymaleic acid, etidronic acid, zinc salt, and the like, wherein the content of the tourmaline is 5-500 g/t (calculated based on solid form); the content of polyaspartic acid, polyepoxysuccinic acid, polymaleic acid and etidronic acid is 2-60 g/t (calculated based on liquid form); and the content of the zinc salt is 0.2-0.8 g/t (calculated based on solid form), is provided. Also disclosed is a method of preparing the terpolymerized corrosion and scale inhibitor used in circulating cooling water of central air conditioning.

Abstract: A network connection device and a cable status detection method are provided. The network connection device is configured to connect and detect a connection cable. The network connection device includes an interface module, a physical layer transmission circuit and a cable status detection module. The interface module connects the connection cable. The physical layer transmission circuit sends signals to the connection cable or receives signals from the connection cable through the interface module. The cable status detection module receives a notification notifying that the physical layer transmission circuit is in a disable state, and detects the status of the connection cable and generates a detection result when the physical layer transmission circuit is in the disable state. In this way, the network connection device may transmit data signals though the connected connection cable and detect the status of the connection cable.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu·m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu·m or less.

Abstract: A substrate conveyance robot has an end effector provided to a robot arm and including a substrate holding unit configured to hold a substrate, arm drive unit configured to drive the robot arm, a robot control unit configured to control the arm drive unit, and a holding force detection unit configured to detect a substrate holding force exerted by the substrate holding unit. The robot control unit controls the arm drive unit based on an upper limit value of at least one of acceleration and speed of the end effector which are determined in accordance with the substrate holding force detected by the holding force detection unit.

Abstract: This invention relates to a solution formulation containing a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a pMDI comprising a canister containing the formulation.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract: A substrate transfer device includes a casing and a substrate conveying robot. A size of the casing in a second direction Y is more than a size of the casing in a first direction X. The casing includes walls forming a conveying chamber and at least one opening or provided at at least one side of the conveying chamber in the first direction X. The substrate conveying robot includes a base, a robot arm, a robot hand, and a controller. When a space in the conveying chamber except for a predetermined exclusive region is defined as an effective conveying chamber, an entire link length DL of a link is less than a conveying chamber size Dx, and an entire hand length Dh of the robot hand is not less than an effective conveying chamber size Dx?.

Abstract: A control unit of a substrate conveying robot makes a robot arm and a substrate holding device execute a blade member advancing operation, a substrate receiving operation, and a substrate placing operation. The substrate holding device is configured to be capable of being switched between a first working state that a pair of blade members are arranged in the vertical direction and a second working state that a pair of blade members are arranged in a position out of the vertical direction and a single blade member can be advanced into a substrate placing structure.

Abstract: This invention relates to a solution formulation comprising a tiotropium salt, 12-20% ethanol, 0.1-1.5% of water, 0.05-0.10% citric acid (or other organic acid) and an HFA propellant, wherein the percentages are percentages by weight based on the total weight of the formulation. The invention also provides a p MDI comprising a canister containing the formulation.

Abstract: An airflow adaptor for a breath-actuated dry powder inhaler. The airflow adaptor includes a conduit having a proximal end and a distal end, wherein the proximal end allows fluid communication from a deagglomerator outlet port to the distal end of the conduit, and wherein the airflow adaptor further includes provisions for allowing air to flow from a proximal end of the adaptor to a distal end of the adaptor independently of the airflow in the conduit when a breath induced low pressure is applied to the distal end of the airflow adaptor.

Abstract: A terpolymerized corrosion and scale inhibitor used in circulating cooling water of central air conditioning, containing tourmaline, polyaspartic acid, polyepoxysuccinic acid, polymaleic acid, etidronic acid, zinc salt, and the like, wherein the content of the tourmaline is 5-500 g/t (calculated based on solid form); the content of polyaspartic acid, polyepoxysuccinic acid, polymaleic acid and etidronic acid is 2-60 g/t (calculated based on liquid form); and the content of the zinc salt is 0.2-0.8 g/t (calculated based on solid form), is provided. Also disclosed is a method of preparing the terpolymerized corrosion and scale inhibitor used in circulating cooling water of central air conditioning.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 ?m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 ?m or less.

Abstract: A polishing pad for use in chemical mechanical polishing of a substrate is disclosed. The polishing pad includes first and second major surfaces. The first major surface forms a polishing surface and is divided into a main portion and edge portions. The edge portions are nearer to edges of the polishing pad while the main portion is between the edge portions and farther from the edges of the polishing pad. The polishing pad also includes a plurality of polishing posts disposed on the first major surface of the pad. The densities of the polishing posts in the edge portions and main portion are different.

Abstract: A nasal spray device for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device includes: a pressurised aerosol canister including a vial containing a pharmaceutical formulation including an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve having a valve stem; and an actuator for the aerosol canister, the actuator including a stem block having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump extending below the receptacle, the stem block further defining a discharge orifice for the pharmaceutical formulation and a transfer channel through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice.

Abstract: A method and system for identifying and processing text operation instruction, and a server are provided. The method includes a communication terminal performing: presenting a communication session window between a user and a network transaction system; receiving text information input by the user in the communication session window, and performing text semantic analysis on the text information to determine an operation type and an operation instruction field; sending the determined operation type and operation instruction field to the network transaction system; and receiving response information returned by the network transaction system, and outputting the response information to the communication session window.

Abstract: Various embodiments provide methods, apparatus, and systems for logging in an application account. A request for logging in an application account sent from a first terminal can be received. It is detected if the first terminal can be included in frequently used terminals corresponding to the application account. First verification information can be sent to a second terminal bound with the application account, when it is detected the first terminal is not included in the frequently used terminals corresponding to the application account. Second verification information can be received from the first terminal to detect if the second verification information matches the first verification information. When it is detected that the second verification information matches the first verification information, the request for logging in the application account can be responded.